Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer
| Autor: | Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Future Oncology. 19:575-586 |
| ISSN: | 1744-8301 1479-6694 |
| DOI: | 10.2217/fon-2022-0977 |
| Popis: | Aim: To describe treatment patterns, healthcare resource utilization and costs in HER2-negative gastric/gastroesophageal (G/GEJ) cancer in the USA. Methods: Retrospective IQVIA Adjudicated Closed Claims database analysis; patients with HER2-negative G/GEJ cancer initiating systemic therapy between October 2016 and December 2019 were identified. Results: Among 1317 patients, platinum plus taxane regimens (54%) were common in neoadjuvant/adjuvant settings. Platinum-taxane (41%) and platinum-fluoropyrimidine (36%) regimens were common first-line therapies in the metastatic setting. Treatment regimens were heterogeneous in later lines. Hospitalization rates ranged from 39% (first-, second-line metastatic settings) to 61% (neoadjuvant/adjuvant setting). High healthcare resource utilization was driven by high outpatient costs. Mean per-patient per-month outpatient costs combining physician office and hospital visits ranged from US$10,944 to $12,582 (representing 52–70% of total costs). Conclusion: For G/GEJ cancer, systemic regimens varied across lines of therapy with variation increasing with subsequent therapy lines; high healthcare costs persist for systemic treatment, particularly outpatient services. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|